John Welsh, MD
Physical Medicine & Rehabilitation · Campbell, CANPI 1003990847
Payments from drug & device makers
Across 14 payments — averaging $55.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- SPR Therapeutics, Inc$256
- Si-bone, Inc.$189
- Boston Scientific$120
- Insulet Corporation$67
- IBSA Pharma Inc.$45
- Relievant Medsystems, Inc.$33
- plus $65 from 3 others
What the payments were for
- Food & beverage$74897%
- Education$263%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| SPR Therapeutics, Inc | 4 | $256 |
| Si-bone, Inc. | 2 | $189 |
| Boston Scientific | 1 | $120 |
| Insulet Corporation | 1 | $67 |
| IBSA Pharma Inc. | 2 | $45 |
| Relievant Medsystems, Inc. | 1 | $33 |
| Medtronic | 1 | $26 |
| Abbott | 1 | $23 |
| Electronic Waveform Lab, Inc. | 1 | $16 |
How this compares
$774 in reported general payments places this provider in the 70th percentile of 830 physical medicine & rehabilitation providers in California.
See all physical medicine & rehabilitation providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 319 | $11,300 |
| OxycontinOxycodone Hcl | 14 | $8,574 |
| Gabapentin | 317 | $7,183 |
| Buprenorphine | 37 | $5,585 |
| Fentanyl | 35 | $3,788 |
| Pregabalin | 123 | $3,712 |
| Celecoxib | 51 | $1,876 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 13 | $1,872 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 94 | $1,731 |
| Methadone Hcl | 35 | $1,396 |
| Duloxetine Hcl | 45 | $998 |
| Tramadol Hcl | 76 | $878 |
| Tramadol Hcl ErTramadol Hcl | 14 | $806 |
| Morphine Sulfate ErMorphine Sulfate | 11 | $496 |
| Oxycodone Hcl | 36 | $393 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Campbell
- Ziyad AyyoubParamount$1.8M
- John ShenFontana$1.3M
- Andrew SkalskySan Diego$463K
- Nanette JoyceSacramento$237K
- Mary OatesSanta Maria$158K
- Jeryl WiensFresno$125K
- Pratik GandhiAnaheim$122K
- Ronald SchillingLong Beach$113K
- Kevin BarretteSan Francisco$84K
- Jeffrey ChenSan Diego$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.